contact us

PLEASE DO NOT LEAVE ANY CONFIDENTIAL TREATMENT DATA, PRIVATE PATIENT DETAILS OR ANY OTHER PROTECTED HEALTH INFORMATION (PHI) ON THIS SITE. THIS IS IN ORDER TO ENSURE PRIVACY AND REGULATORY COMPLIANCE WITH APPLICABLE PRIVACY RULES AND LAWS (INCLUDING BUT NOT LIMITED TO HIPAA).

Bipolar Disorder – Double-Blind Placebo Control Safety and Feasibility Study

Shalvata Mental Health Center, Hod-Hasharon, Israel

13 January, 2009

A double-blinded and placebo-controlled clinical trial has begun at the Shalvata Mental Health Center to explore the efficacy and safety of Braisnway® Deep TMS in 50 subjects with bipolar depression, currently treated with mood stabilizers and previously unsuccessfully treated with antidepressant medication.

The trial is expected to be carried out over the course of 7 weeks in respect of each subject.

This trial is expected to serve as the basis for a broad multi-center trial.